Spyre Therapeutics, Inc.
SYRE
$75.77
$0.730.97%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -69.01M | -62.53M | -11.18M | -36.72M | -44.77M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.39M | 20.22M | -31.87M | -805.00K | 4.35M |
| Change in Net Operating Assets | 244.00K | -2.27M | 5.94M | -9.04M | -568.00K |
| Cash from Operations | -57.37M | -44.58M | -37.12M | -46.56M | -40.99M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -7.00M | 0.00 | 7.00M | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 56.58M | -240.41M | 25.00M | 72.00M | -61.00K |
| Cash from Investing | 56.58M | -247.41M | 25.00M | 79.00M | -61.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 12.43M | 312.88M | 491.00K | 731.00K | 218.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -171.00K | -69.00K | -5.13M | 0.00 | -93.00K |
| Cash from Financing | 12.26M | 312.81M | -4.64M | 731.00K | 125.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.46M | 20.82M | -16.76M | 33.17M | -40.93M |